Celgene Settles Whistle-Blower Fraud Suit for $280 Million
- Company accused of illegally marketing two cancer drugs
- Settlement includes $20.7 million payment to 28 states
This article is for subscribers only.
Celgene Corp. agreed to pay $280 million to resolve a whistle-blower’s claims the drugmaker used illegal marketing tactics to turn its Thalomid and Revlimid cancer drugs into blockbuster sellers, the U.S. said.
The settlement ends claims by a former company saleswoman that Celgene defrauded federal and state Medicare programs out of billions by luring doctors into prescribing the cancer drugs for unapproved uses, Acting U.S. Attorney Sandra Brown in Los Angeles said Tuesday in a statement.